Pharmacy Professor Tackling Alzheimer’s

bvb group photo

As a pharmacist with geriatrics specialty, Kalin Clifford, PharmD, Associate Professor of Pharmacy Practice at the Dallas campus, is involved with the care of many older adults living with Alzheimer’s disease, a brain disorder that slowly destroys memory, thinking skills and the ability to carry out simple tasks.

Kalin Clifford, PharmD

Kalin Clifford, PharmD

“My pharmaceutical care focus is working with Alzheimer’s disease patients who no longer benefit from the medications currently available and those patients at the end of their disease battle,” shared Clifford. “I educate them, and their loved ones, on why medications are no longer working and redefine goals of care with medications that will improve their quality of life during the time they have left.”

According to the Alzheimer’s Association, an estimated 6.5 million Americans age 65 and older are living with Alzheimer’s in 2022. That number is expected to grow as the size of the U.S. population age 65 and older continues to grow.

An Alzheimer’s diagnosis is often disheartening but Clifford is optimistic about the future diagnosis and treatment options that may be available to patients.

BvB Dallas practice

BvB Dallas practice

“Ten years ago, every new medication being created to treat Alzheimer’s was only delaying disease progression,” shared Clifford. “Data being published now shows that identifying Alzheimer’s earlier allows nonpharmacologic methods that help delay the progression of the disease to be performed sooner and helps improve our ability to better identify early warning signs.”

Clifford is also excited about new drugs that are in their Phase III clinical trials that are showing great potential to slow and even stop the progression of Alzheimer’s disease.

“There is hope, and that makes it all the more important to raise awareness for Alzheimer’s disease because these patients need that hope,” said Clifford.

Clifford does his part to raise awareness both through his work and through philanthropic endeavors. Earlier this year, he served as a pink team coach for the BvB Dallas (formerly Blondes vs. Brunettes Dallas) annual powder-puff football game. The game, which acts as a fundraiser for Alzheimer’s awareness and research, raised more than $500,000.

Related Stories

Health

TTUHSC School of Nursing Celebrates 10-Year Anniversary of the Abilene Community Health Center

The TTUHSC School of Nursing hosted a 10-Year Anniversary Celebration and Open House for the Abilene Community Health Center. The center is one of 71 Federally Qualified Health Centers (FQHCs) in Texas according to the Texas Health and Human Services.

Health

TTUHSC Receives $1.3 Million HRSA Telehealth Resource Center Grant to Expand Telehealth in Texas and Louisiana

The TexLa Telehealth Resource Center, based at TTUHSC, has been awarded a $1.3 million, four-year grant from HRSA to strengthen and expand digital health services in Texas and Louisiana.

Health

The Relational Health Center Celebrates Two Years of Care for Families

On Friday, August 22, from 3 - 5 p.m., the Relational Health Center is celebrating its second birthday with an open house event at Covenant Children’s Hospital in Lubbock.

Recent Stories

Research

Abid Brings Hematology Expertise to TTUHSC Oncology Team

Muhammad Bilal Abid, M.D., has joined the TTUHSC School of Medicine oncology team as an associate professor of internal medicine and medical director of TTUHSC’s Blood and Marrow Transplantation & Cellular Therapy Program.

Research

Research Team Studies Cardiovascular Disease Risk in Homeless Population

A team of student researchers from TTUHSC and TTU evaluated differences in CVD risk between men and women experiencing poverty and homelessness in West Texas, a medically underserved region within the TTUHSC service area.

Research

Clinical Trials Provide Access to Latest Cancer Interventions

Beginning in 2008, TTUHSC, through the School of Medicine Pediatric Cancer Research Center in 2025, has conducted multiple phase 1 oncology clinical trials for pediatric and adult cancer patients. These trials will pave new ground for patients now and in the future.